Inozyme CEO Disposes All Shares in BioMarin Acquisition – Form 4 Details

Rhea-AI Filing Summary

Inozyme Pharma, Inc. (INZY) — Insider Form 4 Overview

CEO & Chairman Douglas A. Treco filed a Form 4 detailing the automatic disposition of his entire equity stake following the closing of Inozyme’s merger with BioMarin Pharmaceutical Inc. on 1 July 2025. Under the Agreement and Plan of Merger dated 16 May 2025, BioMarin’s wholly owned Incline Merger Sub acquired all outstanding Inozyme shares for $4.00 cash per share.

• Common stock: 43,861 shares were tendered at $4.00, eliminating Treco’s direct share ownership.
• Restricted stock units: 150,000 RSUs automatically accelerated, vested, and converted to a $4.00 cash payout per underlying share.
• Stock options: 86,979 options (exercise $2.77) and 400,000 options (exercise $1.06) vested and were cancelled in exchange for the cash spread between the $4.00 consideration and each strike price.

Following the transactions, Treco reports zero remaining beneficial ownership, reflecting Inozyme’s status as a wholly owned BioMarin subsidiary. The filing is largely procedural, confirming final insider settlement terms aligned with the previously announced merger.

Insights

M&A Specialist

TL;DR: Filing confirms final insider cash-out as BioMarin completes Inozyme takeover; no residual equity remains.

This Form 4 is a standard post-closing disclosure. All equity instruments—common, RSUs, and in-the-money options—were settled for cash under the $4.00 tender price. The option spread delivers modest incremental value (≈$1.23 and $2.94 per share for the two tranches), but materially the event only reiterates that the merger closed on 1 July 2025 and insiders no longer hold Inozyme stock. Because the deal terms were publicly known since May, the filing has minimal incremental information value for investors and no direct market impact on either BioMarin or any remaining Inozyme securities (which will be delisted).

Portfolio Manager

TL;DR: Routine insider disposition; cash settlement aligns with previously fixed $4.00 exit price.

For portfolio holders, this disclosure merely documents execution mechanics: common holders receive $4.00; option holders capture intrinsic value. There is no change to payout, timing, or tax treatment beyond what the merger proxy outlined. The lack of residual equity confirms the completion of the transaction and removes Inozyme from investable universes. Consequently, the filing is administrative rather than a driver of valuation or trading strategy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Treco Douglas A

(Last) (First) (Middle)

C/O INOZYME PHARMA, INC.

321 SUMMER STREET SUITE 400

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inozyme Pharma, Inc. [ INZY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Chairman

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		U(1)		43,861(2)	D	$4	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	07/01/2025		D(1)			150,000	(3)	(3)	Common Stock	150,000	(3)	0	D
Stock Option (Right to Buy)	$2.77	07/01/2025		D(1)			86,979	(4)	05/27/2030	Common Stock	86,979	(4)	0	D
Stock Option (Right to Buy)	$1.06	07/01/2025		D(1)			400,000	(4)	03/10/2035	Common Stock	400,000	(4)	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").

2. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.

3. Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.

4. Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.

	/s/ Sanjay Subramanian, as attorney-in-fact for Douglas A Treco	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.